pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update
The latest update as of March 31, 2017 has been issued by the pan-Canadian Pharmaceutical Alliance Office (pCPAO). The key highlights are as follows:
- Three new products have initiated pCPA negotiations since the last update, for a total of 30 active negotiations:
- Afinitor (everolimus) for a new indication – treatment of neuroendocrine tumours of gastrointestinal or lung origin
- Campral (acamprosate calcium) used as maintenance of alcohol abstinence
- Votrient (pazopanib hydrochloride) for use in treatment of genitourinary metastatic renal cell carcinoma
- Six negotiations have been completed since the last update, for a total of 148 joint negotiations.
- Five negotiations resulted in a Letter of Intent:
- Entresto (sacubitril/valsartan) for the treatment of heart failure
- Entyvio (vedolizumab) for the treatment of ulcerative colitis
- Entyvio (vedolizumab) for the treatment of Crohn’s disease
- Eylea (aflibercept) for a new indication – treatment of macular edema secondary to branch retinal vein occlusion
- Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) for the treatment of HIV-1 infection
- One negotiation closed with no agreement reached:
- Abilify (aripiprazole) used for the treatment of schizophrenia and related psychotic disorders
- Five negotiations resulted in a Letter of Intent:
- Five new drug products were added to the “No pCPA Negotiations” list
- One product, Fentora (fentanyl buccal) for the treatment of breakthrough cancer pain
- Four products where the pCPA has provided insight into why an agreement could not be reached: “The manufacturers and pCPA jurisdictions have engaged in thorough discussions regarding criteria and conditions as recommended through the HTA review and both recognize that a Letter of Intent (LOI) could not be reached at the current time.”
- Adempas (riociguat) for the treatment of pulmonary arterial hypertension
- Humira (adalimumab) for the treatment of Hidradenitis Suppurativa
- Ilaris (canakinumab) for the treatment of systemic juvenile idiopathic arthritis
- Xgeva (denosumab) for the treatment of skeletal-related events due to bone metastases
Please visit the pCPA website for more information.
To receive updates similar to this one please be sure to sign up for Market Access Signals, our free e-mail newsletter service.
